Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Schwab US Large Cap Growth ETF trades at $35.63 (market cap $65.41B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 67.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Schwab US Large Cap Growth ETF for 52 Days on average.
| MRVI | SCHG | |
|---|---|---|
Market Cap | $972.90M | $65.41B |
Volume | 4,325,710 | 6,607,358 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $36.93 |
52-Week Low | $2.83 | $28.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SCHG trades at $36.59 with no daily change, showing stability amid a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent 20% position reduction by Corient Private Wealth. Recent news highlights SCHG's competitive positioning among large-cap growth ETFs with its 0.03% expense ratio and concentration in megacap technology stocks.
The outlook remains positive given SCHG's historical outperformance versus the S&P 500, though concentration risk in top holdings and potential valuation concerns warrant monitoring. Growth investors may benefit from the ETF's low-cost exposure to leading US companies, but should be aware of narrowing performance gaps with broader market alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
